The level of IL-6 is significantly increased in the intestinal mucosa of IBD patients, and its blockage by a specific monoclonal antibody led to good rates of clinical response in refractory CD but increased the incidence of serious adverse events, probably due to a strong immunosuppression [72]. This evidence concerns the gene IL6 and inflammatory bowel disease.